Efficacy of new inotropic drugs in clinical coronary heart failure.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002395:Catecholamines / Q000494:pharmacology*; D004280:Dobutamine / Q000008:administration & dosage / Q000494:pharmacology*; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007263:Infusions, Parenteral; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010701:Phonocardiography; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D011312:Pressure; D011799:Quinazolines / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects
D002395:Catecholamines; D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D011799:Quinazolines; D004280:Dobutamine; D007545:Isoproterenol